Use of 6-mercapturine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: con.
Griffiths
Anne M
AM
University of Toronto, Toronto, Canada. anne.griffths@sickkids.ca
D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy* / Q000473:pathology; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015122:Mercaptopurine / Q000627:therapeutic use*; D010347:Patient Care Planning; D010641:Phenotype; D017410:Practice Guidelines as Topic; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index
D007166:Immunosuppressive Agents; D015122:Mercaptopurine; D001379:Azathioprine